share_log

Mangoceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

SEC ·  Jul 26 20:03
Summary by Futu AI
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 26, 2024, to deregister 13,220,829 unsold shares of common stock. These shares were initially registered for sale and issuable upon the conversion of 500 shares of Series B Convertible Preferred Stock as part of a previous registration statement (No. 333-278888) declared effective on May 9, 2024. The deregistration follows the full conversion of all 500 shares of Series B Preferred Stock into 2,493,997 shares of common stock, received by the selling stockholder as of July 25, 2024. No additional securities are being deregistered at this time. The company's CEO, Jacob D. Cohen, has signed off on the amendment.
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on July 26, 2024, to deregister 13,220,829 unsold shares of common stock. These shares were initially registered for sale and issuable upon the conversion of 500 shares of Series B Convertible Preferred Stock as part of a previous registration statement (No. 333-278888) declared effective on May 9, 2024. The deregistration follows the full conversion of all 500 shares of Series B Preferred Stock into 2,493,997 shares of common stock, received by the selling stockholder as of July 25, 2024. No additional securities are being deregistered at this time. The company's CEO, Jacob D. Cohen, has signed off on the amendment.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.